All In MedTech

Device Trial Radar · NCT05530889

Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies

Last checked: Nov 20, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 15, 2024

Primary completion

May 13, 2024

Study completion May 13, 2024

Sponsor

Lead sponsor
Johnson & Johnson Vision Care, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 7, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a prospective, randomized, bilateral eye, crossover, non-masked single site pilot study to compare the severity of symptoms of itching between test and control lens after two weeks of wear.

Conditions

  • Ocular Physiology

Interventions

  • TEST LensDevice

    ACUVUE® Theravision® with Ketotifen

  • CONTROL LensDevice

    1-DAY ACUVUE® MOIST.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective rating of itchinessTime frame: up to 2-week follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.